Pharmaceutical Executive August 7, 2024
Partnership with Abbott for Simplera CGM will expand access to the advanced automated insulin delivery.
The FDA has approved Medtronic’s Simplera continuous glucose monitor (CGM), with the company stating that it offers a smaller, more discreet, and user-friendly device to help patients manage their diabetes. Medtronic stated that the approval marks a significant advancement in CGM offerings by eliminating the need for overtape and simplifying the insertion process. Medtronic also announced a global partnership with Abbott to expand CGM options for people living with diabetes.1
“Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and Smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world. We look forward...
Today's Sponsors
Today's Sponsor